Same material, different gradients, different answers
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
The Ledger
Page 22 of 25 of this archive, newest first.
Page 22
Nigeria declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Spain caps tirzepatide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The submitted sample: the weakest link in the whole system
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Why people actually stop, in the order they actually stop
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
Norway declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
A tested vial is evidence about a vial
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Singapore caps tirzepatide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Blind duplicates: what happens when a laboratory does not know it is being watched
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
India caps dulaglutide prescribing to 16 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
South Africa declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Brazil declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Brazil caps dulaglutide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What SURMOUNT-1 tells us about maintenance, and what it does not
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
Mexico declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
What TRIUMPH-3 tells us about maintenance, and what it does not
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
Portugal caps tirzepatide prescribing to 5 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What happens when the drug is taken away: three randomised answers
The regain trajectories, arm by arm, with the estimands named.
Norway caps liraglutide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.